Development of an analytical HPLC methodology to study the effects of thymosin β4 on actin in sputum of cystic fibrosis patients

Annals of the New York Academy of Sciences

Volumn 1270, Issue 1, 2012, Pages 86-92

  Badamchian, Mahnaz ^a   Damavandy, Ali A ^b   Goldstein, Allan L ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Actin; Cystic fibrosis; HPLC; Sputum; Thymosin 4

Indexed keywords

ACTIN; DEOXYRIBONUCLEASE; F ACTIN; G ACTIN; GELSOLIN; THYMOSIN ALPHA1; THYMOSIN BETA4; THYMOSIN FRACTION 5;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ARTICLE; BINDING SITE; CYSTIC FIBROSIS; DEPOLYMERIZATION; DRUG EFFECT; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; SPUTUM ANALYSIS;

EID: 84867338595     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06671.x     Document Type: Article

References (15)

1. Lee, W.M. & R.M. Galibrith. 1992. The extracellular actin-scavenger system and actin toxicity. N. Engl. J. Med. 326, 20: 335-340.
2. Stossel, T.P. 1993. On the crawling of animal cells. Science 260: 106-109.
3. Pollard, T.D. & J.A. Cooper. 1986. Actin and actin-binding proteins. A critical evaluation of mechanisms and functions. Annu. Rev. Biochem. 55: 987-1035.
4. Vasconcellos, C.A., P.G. Allen, M.E. Wohl, et al. 1994. Reduction of viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263: 969-971
5. Potter, J., L.W. Mathews, J. Lemm, et al. 1960. Am. I. Dis. Child. 100: 493-495.
6. Mornet, D. & K. Ue. 1984. Proteolysis and structure of skeletal muscle actin. Proc. Natl. Acad. Sci. USA 81: 3680-3684.
7. Rubin, B.K. 2009. Mucous, phlegm, and sputum in cystic fibrosis. Res. Care 54: 726-732.
8. Low, T.L.K., S.K. Hu & A.L. Goldstein. 1981. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc. Natl. Acad. Sci. USA 78: 1162-1166.
9. Sanders, M.C., A.L. Goldstein & Y.L. Wang. 1992. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc. Natl. Acad. Sci. USA 89: 4678-4682.
10. Mora, C., C.A. Bauman, J.E. Paino, et al. 1997. Biodistribution of synthetic thymosin beta 4 in the serum, urine and major organs of mice. Int. J. Immunopharmacol. 19: 1-8.
11. Badamchian, M., M. Fagarasan, R.L. Danner, et al. 2003. Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int. Immunopharmacol. 3: 1225-1233.
12. Rubin, B.K., A.P. Kater & A.L. Goldstein. 2006. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Chest 130: 433-1440.
13. Kater, A., M.O. Henke & B.K. Rubin. 2007. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin β4. Ann. N.Y. Acad. Sci. 1112: 4-7.
14. 4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin. Biol. Ther. 12: 37-51.
15. Jones, A.P. & C. Wallace. 2010. Dornase alfa for cystic fibrosis. Cochrane Database Syst. Rev. Mar. 17: CD001127.